TX-MARY-KAY/GENDER-GAP
2.9.2022 18:01:39 CEST | Business Wire | Press release
Below is a statement by Julia A. Simon, Chief Legal and Chief Diversity & Inclusion Officer, Mary Kay Inc., on the release of the 2022 World Economic Forum’s Global Gender Gap Report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005218/en/
Julia Simon, Chief Legal Officer and Chief Diversity & Inclusion Officer (Photo Credit: Mary Kay Inc.)
According to a sobering finding from the World Economic Forum’s 2022 Global Gender Gap Report, gender parity is beyond reach in our lifetime. In fact, according to the report, it will take 132 years for gender equality to become a reality and 151 years to close the economic participation and opportunity gender gap. Not a single country from the 146 examined has reached parity.
That’s the bad news.
The good news? There’s still time to change all that. The 2022 findings have shaken me, but they have not deterred me. Nor should they deter you.
Gender equality is a prerequisite not only for human development—but sustainable economic growth. A rich body of data shows that without gender parity it is impossible to reduce poverty, attain food security, address climate impacts, or ensure a more peaceful and inclusive society. Gender parity isn’t a “nice to have.” It’s also not just a perk of developed nations. It is an essential requirement for all countries to develop and prosper.
To mitigate further backsliding, the structural barriers limiting women’s labor market participation, including their re-entry and retention in the workforce following COVID-19, must be addressed. Targeted policies which support women’s talent development in the industries of the future, and which accelerate their advancement to leadership and management positions, are also needed.
The private sector has a critical role to play in addressing gender gaps in the workplace and in developing the pipeline of women for leadership positions. As a company founded by a barrier-breaking businesswoman almost 60 years ago, this is personal to Mary Kay.
In 2019, Mary Kay signed the Women’s Empowerment Principles (WEPs) and in 2021 the company became a Commitment Maker to the Generation Equality Forum Action Coalitions to accelerate progress on gender equality to advance the Sustainable Development Goals.
Mary Kay is participating in the 2022-2023 UN Global Compact Target Gender Equality accelerator programme to continue the implementation of ambitious corporate targets for women’s representation and leadership in the company and in our supply chain. Leading by example and reflecting our belief in increased women’s inclusion, Mary Kay is putting our values and commitments into action:
Women’s Representation and Leadership at Mary Kay (Data from August 2022):
- 62% of our Global Workforce are Women
- 50% of our Executive Team are Women
- 53% of our Vice Presidents and above are Women
- 57% of our Directors and above are Women
- 59% of our Managers and above are Women
- 70% of our Market Leaders are Women
- 60% of our Leaders in our Top 10 Markets are Women
Gender-Responsive Procurement & Supplier Diversity at Mary Kay (U.S. only supply chain data from February 2021):
- 66% of our Procurement Team are Women
- 12% of our Indirect Suppliers are Women, Minority or Veteran-Owned
- 5% of our Direct Suppliers are Women, Minority or Veteran-Owned
Our 10-year Sustainability Strategy, titled Enriching Lives Today for a Sustainable Tomorrow, pursues a holistic approach to advancing gender equality and women’s empowerment with the following key commitments to achieve by 2030:
- Economically empower 5 million women worldwide
- Ensure access to education for 250,000 women and girls globally
- Provide over 10 million women worldwide with gender-based violence support services, and
- Develop a 10-year policy agenda to address women’s rights
Inspired by our mission as an entrepreneurship development company founded by a woman for women, we are committed to advancing women’s entrepreneurship and dismantling the barriers to women’s economic empowerment. We brought this vision to the United Nations in 2019 and, together with 6 UN agencies, we incepted the Women’s Entrepreneurship Accelerator (WEA) to create an enabling ecosystem for women entrepreneurs.
The time to act is now. Sitting on the sidelines and waiting 132 years is simply not an option. The Sustainable Development Impact Meeting on “Advancing Gender Equality”, which takes place in New York this month, is an opportunity for leaders from the public and private sector to identify tools and strategies to close the gender gap. We owe it to future generations to mobilize our efforts to make the transformative changes that are so badly needed for women and girls.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
